
According to data from Benzinga Pro, during Q4, Cue Biopharma's (NASDAQ:CUE) reported sales totaled $8.25 million. Despite a 35.47% increase in earnings, the company posted a loss of $8.38 million. Cue Biopharma collected $2.40 million in revenue during Q3, but reported earnings showed a $12.99 million loss.